Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00163085 | The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease | PHASE2 | COMPLETED | 12 | — | — | May 1, 2005 | Jan 1, 2006 | Sep 22, 2006 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| NR2B NMDA Antagonist CP-101,606 (traxoprodil) | DRUG | - |
Inclusion Criteria: * 30- 80-year-old PD patients (UK Parkinson's Disease Brain Bank criteria) with a Hoehn \& Yahr stage score of 2-5 in the "off" state. Exclusion Criteria: * Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal...